{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:28:53Z","timestamp":1756895333340},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,22]]},"DOI":"10.7759\/cureus.65112","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T15:41:48Z","timestamp":1721662908000},"source":"Crossref","is-referenced-by-count":3,"title":["Combination of Imipenem-Cilastatin-Relebactam and Amoxicillin in the Antibiotic Regimen in Two Cases of Mycobacterium abscessus Lung Infection"],"prefix":"10.7759","author":[{"given":"Anastasios I","family":"Vogiatzoglou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Hadji \u039citrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sionidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Nikopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan\u03bfurios","family":"Kontos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Papaventsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Papavasileiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Manika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus","volume":"10","author":"Lopeman RC","year":"2020","unstructured":"Lopeman RC, Harrison J, Rathbone DL, Desai M, Lambert PA, Cox JA. Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus. Sci Rep. 2020, 10:928. 10.1038\/s41598-020-57844-8","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcsw.2021.100064","article-title":"In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex","volume":"7","author":"Harrison J","year":"2021","unstructured":"Harrison J, Weaver JA, Desai M, Cox JA. In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex. Cell Surf. 2021, 7:100064. 10.1016\/j.tcsw.2021.100064","journal-title":"Cell Surf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.659997","article-title":"Mycobacterium abscessus complex: a review of recent developments in an emerging pathogen","volume":"11","author":"Victoria L","year":"2021","unstructured":"Victoria L, Gupta A, G\u00f3mez JL, Robledo J. Mycobacterium abscessus complex: a review of recent developments in an emerging pathogen. Front Cell Infect Microbiol. 2021, 11:659997. 10.3389\/fcimb.2021.659997","journal-title":"Front Cell Infect Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.08.035","article-title":"Epidemiology of Mycobacterium abscessus","volume":"30","author":"Cristancho-Rojas C","year":"2024","unstructured":"Cristancho-Rojas C, Varley CD, Lara SC, Kherabi Y, Henkle E, Winthrop KL. Epidemiology of Mycobacterium abscessus. Clin Microbiol Infect. 2024, 30:712-7. 10.1016\/j.cmi.2023.08.035","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00128-2","article-title":"Epidemiology of Mycobacterium abscessus in England: an observational study","volume":"2","author":"Lipworth S","year":"2021","unstructured":"Lipworth S, Hough N, Weston N, et al.. Epidemiology of Mycobacterium abscessus in England: an observational study. Lancet Microbe. 2021, 2:e498-507. 10.1016\/S2666-5247(21)00128-2","journal-title":"Lancet Microbe"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto RA","year":"2016","unstructured":"Floto RA, Olivier KN, Saiman L, et al.. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax. 2016, 71:88-90. 10.1136\/thoraxjnl-2015-207983","journal-title":"Thorax"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60632-7","article-title":"Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study","volume":"381","author":"Bryant JM","year":"2013","unstructured":"Bryant JM, Grogono DM, Greaves D, et al.. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013, 381:1551-60. 10.1016\/S0140-6736(13)60632-7","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2021.100244","article-title":"Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease","volume":"24","author":"Pennington KM","year":"2021","unstructured":"Pennington KM, Vu A, Challener D, Rivera CG, Shweta FN, Zeuli JD, Temesgen Z. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis. 2021, 24:100244. 10.1016\/j.jctube.2021.100244","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2016.79.2.74","article-title":"Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians\u2019 perspectives","volume":"79","author":"Ryu YJ","year":"2016","unstructured":"Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians\u2019 perspectives. Tuberc Respir Dis (Seoul). 2016, 79:74-84. 10.4046\/trd.2016.79.2.74","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley CL","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al.. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020, 56:10.1183\/13993003.00535-2020","journal-title":"Eur Respir J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith DE","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, et al.. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007, 175:367-416. 10.1164\/rccm.200604-571ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00516-19","article-title":"GenoType NTM-DR performance evaluation for identification of Mycobacterium avium complex and Mycobacterium abscessus and determination of clarithromycin and amikacin resistance","volume":"57","author":"Huh HJ","year":"2019","unstructured":"Huh HJ, Kim SY, Shim HJ, et al.. GenoType NTM-DR performance evaluation for identification of Mycobacterium avium complex and Mycobacterium abscessus and determination of clarithromycin and amikacin resistance. J Clin Microbiol. 2019, 57:10.1128\/JCM.00516-19","journal-title":"J Clin Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01000-6","article-title":"Therapeutic drug monitoring in non-tuberculosis mycobacteria infections","volume":"60","author":"Alffenaar JW","year":"2021","unstructured":"Alffenaar JW, M\u00e4rtson AG, Heysell SK, et al.. Therapeutic drug monitoring in non-tuberculosis mycobacteria infections. Clin Pharmacokinet. 2021, 60:711-25. 10.1007\/s40262-021-01000-6","journal-title":"Clin Pharmacokinet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz433","article-title":"Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab \u03b2-lactamase on the in vitro and intracellular efficacy of imipenem","volume":"75","author":"Le Run E","year":"2020","unstructured":"Le Run E, Atze H, Arthur M, Mainardi JL. Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab \u03b2-lactamase on the in vitro and intracellular efficacy of imipenem. J Antimicrob Chemother. 2020, 75:379-83. 10.1093\/jac\/dkz433","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186793","article-title":"Alternative and experimental therapies of Mycobacterium abscessus infections","volume":"21","author":"Meir M","year":"2020","unstructured":"Meir M, Barkan D. Alternative and experimental therapies of Mycobacterium abscessus infections. Int J Mol Sci. 2020, 21:10.3390\/ijms21186793","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106938","article-title":"In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates","volume":"62","author":"Burke A","year":"2023","unstructured":"Burke A, Carter R, Tolson C, et al.. In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates. Int J Antimicrob Agents. 2023, 62:106938. 10.1016\/j.ijantimicag.2023.106938","journal-title":"Int J Antimicrob Agents"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106669","article-title":"In vitro effects of diazabicyclooctane \u03b2-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex","volume":"60","author":"Misawa K","year":"2022","unstructured":"Misawa K, Nishimura T, Kashimura S, et al.. In vitro effects of diazabicyclooctane \u03b2-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. Int J Antimicrob Agents. 2022, 60:106669. 10.1016\/j.ijantimicag.2022.106669","journal-title":"Int J Antimicrob Agents"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02623-18","article-title":"In vitro activity of the new \u03b2-lactamase inhibitors relebactam and vaborbactam in combination with \u03b2-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik A","year":"2019","unstructured":"Kaushik A, Ammerman NC, Lee J, et al.. In vitro activity of the new \u03b2-lactamase inhibitors relebactam and vaborbactam in combination with \u03b2-lactams against Mycobacterium abscessus complex clinical isolates. Antimicrob Agents Chemother. 2019, 63:10.1128\/AAC.02623-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00528-23","article-title":"The in vitro effect of new combinations of carbapenem-\u03b2-lactamase inhibitors for Mycobacterium abscessus","volume":"67","author":"Fr\u00f6berg G","year":"2023","unstructured":"Fr\u00f6berg G, Ahmed A, Chryssanthou E, Davies Forsman L. The in vitro effect of new combinations of carbapenem-\u03b2-lactamase inhibitors for Mycobacterium abscessus. Antimicrob Agents Chemother. 2023, 67:e0052823. 10.1128\/aac.00528-23","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen MD","year":"2020","unstructured":"Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020, 18:392-407. 10.1038\/s41579-020-0331-1","journal-title":"Nat Rev Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A \u03b2-lactamase","volume":"69","author":"Soroka D","year":"2014","unstructured":"Soroka D, Dub\u00e9e V, Soulier-Escrihuela O, et al.. Characterization of broad-spectrum Mycobacterium abscessus class A \u03b2-lactamase. J Antimicrob Chemother. 2014, 69:691-6. 10.1093\/jac\/dkt410","journal-title":"J Antimicrob Chemother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the l,d-transpeptidases and d,d-carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa KM","year":"2020","unstructured":"Dousa KM, Kurz SG, Taracila MA, et al.. Insights into the l,d-transpeptidases and d,d-carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors. Antimicrob Agents Chemother. 2020, 64:10.1128\/AAC.00098-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2023.100381","article-title":"Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-relebactam and rifabutin","volume":"32","author":"Beech AJ","year":"2023","unstructured":"Beech AJ, Weinberg SE, Mortimer AE, Lynch F, Bedford J, Calisti G. Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-relebactam and rifabutin. J Clin Tuberc Other Mycobact Dis. 2023, 32:100381. 10.1016\/j.jctube.2023.100381","journal-title":"J Clin Tuberc Other Mycobact Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264665-combination-of-imipenem-cilastatin-relebactam-and-amoxicillin-in-the-antibiotic-regimen-in-two-cases-of-mycobacterium-abscessus-lung-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T15:41:53Z","timestamp":1721662913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264665-combination-of-imipenem-cilastatin-relebactam-and-amoxicillin-in-the-antibiotic-regimen-in-two-cases-of-mycobacterium-abscessus-lung-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.65112","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}